Photo via South China Morning Post

Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts

Read the original at South China Morning Post ↗
Cite

Shen, X. (2026, September 23). Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts. South China Morning Post. https://www.scmp.com/business/markets/article/3368445/rising-us-scrutiny-clinical-trials-could-threaten-chinas-biotech-advantage-analysts?utm_source=rss_feed

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

South China Morning Post · collected 2026-09-23 · by Xinmei Shen

Quick Summary

Analysts warn that increasing scrutiny from the United States on clinical trials may jeopardize China's competitive edge in biotech due to its reputation for conducting such trials quickly and inexpensively. US lawmakers and FDA officials are expressing concerns about American pharmaceutical companies' reliance on early-stage clinical trials in China, citing issues of transparency and a desire to retain medical innovation within the country. This could lead firms to more carefully evaluate Chinese assets and possibly reduce their reliance on Chinese trial data.
Written by AI on 2026-09-23, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

US lawmakers and FDA officials are increasingly concerned about American pharmaceutical companies conducting early clinical trials in China, citing issues with transparency and the need to maintain medical innovation within the country. This scrutiny could jeopardize China’s competitive edge in the biotech sector, which has been built on its capability to swiftly and economically conduct these trials. According to Xianfeng Morgan Xu from US law firm Foley Hoag, this heightened concern may lead companies to more carefully assess assets originating from China, potentially limiting their growth opportunities in the global market.

Written for “US Scrutiny Of Chinese Biotech” on 2026-11-03, grounded in this article and the 0 other(s) covering the same event.

Story

📰 US Scrutiny Of Chinese Biotech
Politics · 1 article(s) covering the same event.

Compared with similar articles

This article reads leans right and hedges 75% of its claims. Each row says how that neighbour differs.
America warned it is becoming dangerously reliant on China for new medicines Different event
The Independent
Hedges 6 of 26 claims Outlet record 59/100
“The articles discuss different aspects of U.S. policy toward Chinese biotech and pharmaceutical industries, not a single specific incident.”
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
4
sentences that state something as happening or true
Uncertain
75%
3 of 4 hedged ("reportedly", "may", "according to")
Leaning
Leans right
of the writing, not the subject · beta estimate
Publisher signals
62/100
South China Morning Post's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Politics
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-09-23 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

South China Morning Post · 3686 article(s) · 8 correction(s) detected
Running correction rate · 8 correction(s)
2026-11-03
Singapore hit-and-run: organiser of fund for orphaned boy vows transparency
2026-11-01
Former Apple Daily publisher joins mainland China tour for rehabilitated offenders
2026-10-16
Nobel Peace Prize: the message behind Navi Pillay’s win
2026-10-16
Indonesian governor’s Singapore trip adds fury to forest fire, haze crisis
2026-10-04
Flight to Okinawa diverts back to Hong Kong after suspected landing gear fault
2026-10-04
Tennessee prisons chief resigning after botched execution of Christa Pike
2026-09-29
Indonesian prison chief suspended over secret VIP compound for inmates
2026-09-28
Trump ‘arms offer’ to China jolts Washington into moves to contain the fallout

Who wrote this

Xinmei Shen
12 article(s) here · 1 carrying a prediction
🔮 Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion.
2026-09-26 · assertive framing · China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
🔮 Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
2026-09-23 · speculative framing · Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
Also by Xinmei Shen
Tokenised gold bar to advance Hong Kong’s ambitions as digital, metal trading hub
2026-11-03 · South China Morning Post
How Hong Kong’s fintech strategy is progressing – and where growth still lags
2026-11-02 · South China Morning Post
Chinese drug sector’s stature grows at major cancer conference
2026-10-28 · South China Morning Post
Former HSBC executive launches wealth platform powered by team of AI agents
2026-10-12 · South China Morning Post
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 12 articles by Xinmei Shen →

Topics

China FDA Washington the Food and Drug Administration the United States

Subjects

China GPE · 5× Washington GPE · 2× American NORP · 1× FDA ORG · 1× Foley Hoag ORG · 1× Xianfeng Morgan Xu PERSON · 1× the Food and Drug Administration ORG · 1× the United States GPE · 1×

Narrative

US lawmakers and officials at the Food and Drug Administration (FDA) have raised the alarm about American pharmaceutical companies’ growing reliance on conducting early clinical trials in China, flagging the opaqueness of the process and the need to keep medical innovations on shore.
framing: speculative · carried by 1 article(s) · first seen 2026-09-23
🔮 Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
2026-09-23 · South China Morning Post
Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts · speculative framing

Claims (4 extracted, 3 hedged)

Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts uncertain
scrutiny → rise → analysts
China’s ability to conduct clinical trials quickly and cheaply has given it an edge in the biotech sector – and the US is growing concerned China’s edge in fast, cost-effective early clinical trials has propelled its emergence as a global biopharmaceutical powerhouse, but there is a risk that the United States could take steps to curb that advantage, according to analysts. uncertain
States → conduct → analysts
US lawmakers and officials at the Food and Drug Administration (FDA) have raised the alarm about American pharmaceutical companies’ growing reliance on conducting early clinical trials in China, flagging the opaqueness of the process and the need to keep medical innovations on shore. asserted
lawmakers → raise → shore
While large multinational corporations’ compliance teams have been “on high alert for quite a while”, the recent ratcheting up of such rhetoric in Washington could prompt firms to “double click a lot more when evaluating China-origin target assets”, said Xianfeng Morgan Xu, a partner at US law firm Foley Hoag based in Washington. uncertain
Xu → prompt → Washington
💬Give feedback
🕘History 🎫Support
Terms · Privacy · beta v2.0.0
Articles to 3 Nov 2026